CTI BioPharma (CTIC) Tumbles On FDA Decision; Marc Benioff Sees Potential In Fitbit (FIT)


Shares of CTI BioPharma Corp. (Nasdaq:CTIC) plunged to touch a new 52-week low in early trade Wednesday after the company said that the Investigational New Drug application for its myelofibrosis treatment candidate pacritinib has been placed on full clinical hold by the FDA.

Several brokerage firms downgraded the company’s stock following FDA’s decision – Piper Jaffray from Overweight to Neutral, WallachBeth from Hold to Sell and Ladenburg Thalmann from a Buy to a Neutral rating

CTIC stock is currently exchanging hands at $0.29, down $0.21 (or -42.00%), and 15,356,594 of its shares were traded so far, a large increase in activity versus its average volume (3m) of 1,971,560

CTI BioPharma, a biopharmaceutical company, has 281.79M Shares Outstanding and CTIC stock one-year range is between $0.26 and $2.94 per share



The price Fitbit Inc. (NYSE:FIT) stock surged on Wednesday’s trading session after Salesforce.com (NYSE:CRM) CEO Marc R. Benioff disclosed in a regulatory filing with the SEC ( SC 13G ) a 5.3% stake (5,311,824 shares) in the company

Separately, investment firm Vanguard Group also reported in a SEC filing ( SC 13G/A ) an 11.27% stake (6,948,867 shares) in Fitbit

FIT stock is trading at $14.99, up $0.69 (or +4.82%), and 3,959,868 of its shares exchanged hands so far

Fitbit, which manufactures and provides wearable fitness-tracking devices worldwide, has 59.06M Shares Outstanding and FIT stock 52-week range is from $13.99 to $51.90 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/